Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 9/20 | 0.57 |
| ▸ | CA1 | P00915 | 1/20 | 0.41 |
| ▸ | CA2 | P00918 | 1/20 | 0.41 |
| ▸ | CA4 | P22748 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | NOS3 | P29474 | 4/20 | 0.35 |
| ▸ | NOS1 | P29475 | 4/20 | 0.35 |
| ▸ | NOS2 | P35228 | 4/20 | 0.35 |
| ▸ | OR51E2 | Q9H255 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | FKBP5 | Q13451 | 1/20 | 0.33 |
| ▸ | DDB1 | Q16531 | 4/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20329585 | 0.81 | CRBN (0.46) | CRBNCA1CA2CA4KMT2A | |
| SCHEMBL10726202 | 0.79 | OR51E2 (0.52) | CRBNCA1CA2CA4KMT2A | |
| SCHEMBL441622 | 0.77 | — | — | |
| SCHEMBL7626928 | 0.76 | — | — | |
| SCHEMBL8054160 | 0.76 | — | — | |
| SCHEMBL2482225 | 0.76 | — | — | |
| SCHEMBL2689503 | 0.76 | TRIM24 (0.50) | CA1CA2CA4KMT2ANOS3 | |
| SCHEMBL10726192 | 0.75 | OR51E2 (0.52) | CRBNCA1CA2CA4KMT2A | |
| SCHEMBL5778743 | 0.74 | CRBN (1.00) | CRBNKMT2AOR51E2MEN1TSHR | |
| SCHEMBL1335950 | 0.74 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11324827-B2 | Multifunctionalized polyethylene glycol derivative and preparation method therefor | XIAMEN SINOPEG BIOTECH CO., LTD. (CN) | 2022-05-10 | — | — | US | disclosed |
| US-10434182-B2 | Eight-arm polyethylene glycol derivative, production method therefor, and modified bio-related substance thereof | XIAMEN SINOPEG BIOTECH CO., LTD. (CN) | 2019-10-08 | — | — | US | disclosed |
| US-20180214561-A1 | EIGHT-ARM POLYETHYLENE GLYCOL DERIVATIVE, PRODUCTION METHOD THEREFOR, AND MODIFIEDBIO-RELATEDSUBSTANCETHEREOF | XIAMEN SINOPEG BIOTECH CO., LTD. (CN) | 2018-08-02 | — | — | US | disclosed |
| US-20170312363-A1 | MULTIFUNCTIONALIZED POLYETHYLENE GLYCOL DERIVATIVE AND PREPARATION METHOD THEREFOR | XIAMEN SINOPEG BIOTECH CO., LTD. (CN) | 2017-11-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10434182-B2 | Eight-arm polyethylene glycol derivative, production method therefor, and modified bio-related substance thereof | MRPL38, ALG8, MRPS18A | CRBN 2259/4885CA1 2605/4885CA2 4307/4885 |
| US-20180214561-A1 | EIGHT-ARM POLYETHYLENE GLYCOL DERIVATIVE, PRODUCTION METHOD THEREFOR, AND MODIFIEDBIO-RELATEDSUBSTANCETHEREOF | MRPL38, CXCL8, ALG8 | CRBN 1809/4885CA1 2687/4885CA2 4355/4885 |
| US-11324827-B2 | Multifunctionalized polyethylene glycol derivative and preparation method therefor | HDGF, F11, F12 | CRBN 2558/4885CA1 3481/4885CA2 4828/4885 |
| US-20170312363-A1 | MULTIFUNCTIONALIZED POLYETHYLENE GLYCOL DERIVATIVE AND PREPARATION METHOD THEREFOR | HDGF, F11, F12 | CRBN 2558/4885CA1 3481/4885CA2 4828/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.